Liver Transplant; Complications
Conditions
Brief summary
In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury. Remarkably, it has been reported that a severe vWF/ADAMTS13 imbalance develops during liver transplantation (LT) and persists even after LT. Such changes are thought to contribute to postoperative thrombotic complications, which may lead to early adverse events of thrombotic microangiopathy after living-donor LT (LDLT). We investigated whether vWFPCR could predict EAD or graft failure following LT and compared it with FVIIIPCR, procoagulant, such as vWF and FVIII and anticoagulant, such as PC.
Interventions
PROCEDURELT
Liver transplantation
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
patients who underwent LT
Exclusion criteria
deceased-donor liver transplant, and insufficient data, ABO-incompatible LT
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Early allograft dysfunction | within 7 days after surgery | Immediate liver graft function |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Graft failure | 90 days | re-liver transplantation or death, whichever was first |
| intensive care unit stay | until the day of patients moving to general wards, through study completion, an average of 1 year | days of intensive care unit stay after liver transplant |
Countries
South Korea
Outcome results
None listed